We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Now for phase II

26 April 2012 By Chris Hughes

The old CEO is gone and a new chairman will come faster than planned. The board has moved decisively to address shareholder concerns about strategy and performance. But the pharma group’s difficulties are ingrained in its psyche. The company needs more than new leaders.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)